Clinical trials
Acute on Chronic Hepatic Failure clinical trials
Below are recruiting acute on chronic hepatic failure clinical trials, each written for real people, not researchers. We’re tracking 84 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04953910RecruitingPhase 1
Oral decitabine for cancers with liver problems
This Phase 1 trial studies how a pill form of decitabine/cedazuridine behaves in the body and how safe it is for people whose livers don’t work normally. It may help doctors better understand dosing and safety in patients with hepatic impairment.
Houston, TexasAges 18 years+ - NCT05442710RecruitingPhase 2
Immune cell treatment for recovery from severe septic shock
This trial tests an immune-cell treatment given outside the body to help people recover from septic shock, a life-threatening reaction to infection. It aims to improve survival and organ recovery in patients who are still very ill despite standard care.
Freiburg im Breisgau, Baden-WurttembergAges 18 years+ - NCT05793996RecruitingPhase 4
Testing an iron infusion for iron deficiency in HFpEF
This study checks how common iron deficiency is in people with HFpEF (heart failure with preserved pumping strength) and tests whether an iron infusion (Ferinject®) improves health. It targets people with stable heart symptoms and lab results showing low iron stores or related iron deficiency.
TomskAges 18 years+ - NCT06656299Recruiting
Nerve block for gallbladder removal surgery
This study tests a nerve block called EOIB to see if it helps reduce pain after gallbladder removal surgery. If you are having planned gallbladder surgery, this might be a good option for you.
IstanbulAges 18–65 - NCT06726109Recruiting
FOCUS study on acute heart failure
This trial is studying patients admitted to the hospital for acute heart failure. It will collect information to better understand and treat people with low heart pumping strength (ejection fraction less than 40%) and fluid retention.
Genk, BelgiumAges Any age - NCT07044830Recruiting
Sleep apnea treatment for stroke recovery
This trial tests whether treating sleep apnea with a CPAP machine soon after a stroke can improve recovery. It is for people who had their first moderate-to-severe ischemic stroke and have not used CPAP before.
Ribeirão Preto, São PauloAges 18–80 - NCT03676504RecruitingPhase 1/Phase 2
CAR T cell therapy for relapsed CD19 blood cancers
This trial tests a type of personalized immune treatment (CD19 CAR T cells made from your T cells) for adults (and children with ALL) whose CD19-positive blood cancer has come back or didn’t respond. It may help your immune system recognize and attack cancer cells that still have CD19.
HeidelbergAges 3 years+ - NCT03595917RecruitingPhase 1
New and hard-to-treat BCR-ABL leukemia drugs plus prednisone and blinatumomab
This Phase 1 study tests a combination of targeted cancer drugs with prednisone and blinatumomab in people with BCR-ABL–positive B-cell leukemia (B-ALL), or chronic myeloid leukemia (CML) in lymphoid blast crisis. It may help by attacking leukemia cells through multiple pathways, especially when standard intensive chemotherapy is not suitable.
Chicago, IllinoisAges 18 years+ - NCT06953921Recruiting
Liver disease and confusion: does albumin level matter?
This study looks at whether low albumin levels in the blood are linked to more severe confusion caused by liver disease. It may help doctors understand how to better manage hepatic encephalopathy.
SohagAges 18 years+ - NCT03666000RecruitingPhase 1
Testing a CD19 CAR T cell treatment for relapsed blood cancers
This Phase 1 study tests the safety and best dose of a CD19 CAR T cell therapy (azer-cel) in people whose B-cell blood cancer has returned or did not respond to treatment. It may help people with relapsed/refractory B-ALL or certain aggressive or large B-cell lymphomas, including after or before prior CAR T treatment.
Gilbert, ArizonaAges 18 years+ - NCT05636514RecruitingPhase 1
Testing epigenetic and sensitizer treatment for AML and MDS
This early-phase trial tests whether a combination of targeted medicines can improve outcomes in people with higher-risk MDS or certain types of AML or CMML. It’s designed to find the safest dose and learn if the treatment can help the cancer respond.
Sydney, New South WalesAges 18 years+ - NCT06037018RecruitingPhase 1
Study of CC312 for B-cell blood cancers
This trial tests a new drug called CC312 for people with B-cell blood cancers that have come back or stopped responding to treatment. CC312 is designed to target CD19 on cancer cells, and the study checks if it is safe and how the body handles it.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT03670966RecruitingPhase 1/Phase 2
Targeted iodine therapy, then donor transplant for hard leukemias
This trial tests an antibody-linked radioactive iodine treatment, followed by a donor stem cell transplant, for people with relapsed or refractory high-risk acute leukemia or certain MDS. It may help patients by targeting leukemia cells and then using a new immune system to control the disease.
Seattle, WashingtonAges 18–75 - NCT03852407RecruitingPhase 2
Two kinds of conditioning before matched stem cell transplant
This trial compares two reduced-intensity conditioning regimens before you receive stem cells from a donor who matches your HLA type. It aims to find which approach works better and is safer for certain blood cancers.
AntwerpAges 18–75 - NCT05346393Recruiting
TIPS procedure for kidney failure in people with cirrhosis
This trial studies whether a liver procedure called TIPS can help people with cirrhosis who develop sudden kidney failure (HRS-AKI). It aims to improve kidney function and overall outcomes, but participation depends on several safety checks.
AachenAges 18–80 - NCT07029503RecruitingPhase 2
Heart failure and kidney function study
This trial tests a new treatment for people with heart failure and severely reduced kidney function. It aims to see if the treatment can help protect both the heart and kidneys.
StockholmAges 18 years+ - NCT03459534RecruitingPhase 3
Radotinib for CML patients after prior TKI failure
This trial tests radotinib (a targeted pill) in people with chronic-phase Philadelphia chromosome–positive CML whose previous TKIs stopped working or could not be tolerated. It aims to improve control of the leukemia while checking safety.
BarnaulAges 18 years+ - NCT04256317RecruitingPhase 2/Phase 3
Azacitidine pills with or without venetoclax for certain blood cancers
This study tests whether a pill form of azacitidine (ASTX030) helps people with myelodysplastic syndromes (MDS), CMML, or AML. Some groups may also receive venetoclax; the goal is better blood cancer control for people who aren’t good candidates for intensive chemotherapy.
Los Angeles, CaliforniaAges 18 years+ - NCT05584761RecruitingPhase 1/Phase 2
Cord blood stem cells plus azacitidine for advanced blood cancers
This trial tests whether adding donated cord blood stem cells to azacitidine can improve outcomes for people with advanced MDS, CMML-2, or a certain type of AML. It may help by giving the treatment a stronger chance to control abnormal blood-forming cells.
Nanjing, JiangsuAges 18–80 - NCT06111612Recruiting
Intensive chemo before stem cell transplant for myeloid cancers with spread outside marrow
This trial tests a stronger chemotherapy combination before a donor stem cell transplant for people with certain blood cancers (like AML, MDS, or CMML) that have spread to other parts of the body, such as the skin, testicles, or central nervous system. The goal is to see if this approach can improve outcomes for patients whose disease is in remission.
Shanghai, Shanghai MunicipalityAges 18–55 - NCT03383419RecruitingPhase 2
Hepatitis C–safe antiviral plan for heart transplant recipients
This Phase 2 trial tests giving newer hepatitis C medicines in a careful way to people getting a heart transplant who currently do not have hepatitis C in their blood. The goal is to lower hepatitis C infection risk from donated organs while keeping transplant outcomes safe.
Los Angeles, CaliforniaAges 18–90 - NCT07205315RecruitingEarly Phase 1
Testing GT801 cell therapy for blood cancer and AIHA
This study tests an investigational cell therapy called GT801 for people whose CD19-positive blood cancer (B-ALL, CLL, or B-NHL) or autoimmune hemolytic anemia (AIHA) has not responded to standard treatments. The therapy is made from your own immune cells, modified to target and destroy cancer cells or abnormal immune cells.
Zhengzhou, HenanAges 18–75 - NCT05800210RecruitingPhase 2
T cell and B cell immune “wipeout” after stem cell transplant
This Phase 2 trial studies whether removing certain immune cells (alpha/beta T cells and CD19+ B cells) around the time of a stem cell transplant can improve outcomes for people with high-risk blood cancers. It may help by reducing the immune responses that can interfere with the transplant working, while keeping the process safe.
Gainesville, FloridaAges 6 months–39 years - NCT06420492RecruitingPhase 2
New treatments for severe ulcerative colitis flare
This trial tests new therapies for people with a severe UC flare that hasn't improved after 5 days of high-dose steroids. It aims to find more effective options to control symptoms and avoid hospitalization.
Chestnut Hill, MassachusettsAges 18–75
Hear when a new Acute on Chronic Hepatic Failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for acute on chronic hepatic failure?
- Yes. Clin2 currently lists 84 recruiting acute on chronic hepatic failure studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a acute on chronic hepatic failure trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a acute on chronic hepatic failure trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.